Reviews Of Anti‐infective Agents: Maraviroc: The First of a New Class of Antiretroviral Agents
Open Access
- 15 July 2008
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 47 (2) , 236-241
- https://doi.org/10.1086/589289
Abstract
Maraviroc is the first US Food and Drug Administration-approved drug from a new class of antiretroviral agents that targets a host protein, the chemokine receptor CCR5, rather than a viral target. Binding of maraviroc to this cell-surface protein results in blocking human immunodeficiency virus type 1 (HIV-1) attachment to the coreceptor and prevents the virus from entering CD4+ cells. In this review, we include the details of the discoveries that led to the development of this drug. The drug's pharmacology, including pharmacokinetics and drug interactions, is discussed, as are the clinical efficacy studies that led to licensure. HIV-1 mechanisms of resistance to maraviroc, assays to determine viral coreceptor use (tropism), drug safety, and clinical use of maraviroc are discussed at length.Keywords
This publication has 24 references indexed in Scilit:
- Evaluation of Eight Different Bioinformatics Tools To Predict Viral Tropism in Different Human Immunodeficiency Virus Type 1 SubtypesJournal of Clinical Microbiology, 2008
- Hepatotoxicity Observed in Clinical Trials of Aplaviroc (GW873140)Antimicrobial Agents and Chemotherapy, 2008
- Reduced Maximal Inhibition in Phenotypic Susceptibility Assays Indicates that Viral Strains Resistant to the CCR5 Antagonist Maraviroc Utilize Inhibitor-Bound Receptor for EntryJournal of Virology, 2007
- Development and Characterization of a Novel Single-Cycle Recombinant-Virus Assay To Determine Human Immunodeficiency Virus Type 1 Coreceptor TropismAntimicrobial Agents and Chemotherapy, 2007
- Emergence of CXCR4-Using Human Immunodeficiency Virus Type 1 (HIV-1) Variants in a Minority of HIV-1-Infected Patients following Treatment with the CCR5 Antagonist Maraviroc Is from a Pretreatment CXCR4-Using Virus ReservoirJournal of Virology, 2006
- G-Protein-coupled receptor-protein interactions: Basis for new concepts on receptor structure and functionClinical and Experimental Pharmacology and Physiology, 2005
- SPECIES DIFFERENCES IN THE DISPOSITION OF THE CCR5 ANTAGONIST, UK-427,857, A NEW POTENTIAL TREATMENT FOR HIVDrug Metabolism and Disposition, 2005
- Early Viral Load and CD4+T Cell Count, But Not Percentage of CCR5+or CXCR4+CD4+T Cells, Are Associated with R5-to-X4 HIV Type 1 Virus EvolutionAIDS Research and Human Retroviruses, 2003
- CC CKR5: A RANTES, MIP-1α, MIP-1β Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1Science, 1996
- The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirusNature, 1984